Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel
NASDAQ:HTFL

Heartflow Q2 2025 Earnings Report

Heartflow logo
$47.39 -2.78 (-5.54%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$47.66 +0.27 (+0.58%)
As of 04:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Heartflow EPS Results

Actual EPS
-$1.46
Consensus EPS
-$0.20
Beat/Miss
Missed by -$1.26
One Year Ago EPS
N/A

Heartflow Revenue Results

Actual Revenue
$43.42 million
Expected Revenue
$43.20 million
Beat/Miss
Beat by +$220.00 thousand
YoY Revenue Growth
N/A

Heartflow Announcement Details

Quarter
Q2 2025
Date
9/19/2025
Time
After Market Closes
Conference Call Date
Friday, September 19, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Heartflow's Q2 2025 Quarterly ReportQuarterly Report
(10-Q)

Heartflow Earnings Headlines

Heartflow (NASDAQ:HTFL) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31042951
Insider Selling: Heartflow (NASDAQ:HTFL) CFO Sells $379,783.69 in Stock
September 21 at 4:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036575
Elon gets it. Do you?
Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news. Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point.tc pixel
September 24 at 1:00 AM  |  Porter & Company (Ad)
Heartflow (NASDAQ:HTFL) CFO Sells $850,874.50 in Stock
September 21 at 4:09 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036331
Insider Selling: Heartflow (NASDAQ:HTFL) CFO Sells $230,752.32 in Stock
September 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031309
BCSM Exits Heartflow (HTFL) on Competitive Concerns
September 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/bcsm-exits-heartflow-htfl-competitive-124947141.html
See More Heartflow Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Heartflow? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Heartflow and other key companies, straight to your email.

About Heartflow

Heartflow (NASDAQ:HTFL) is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.

The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFRCT). This information can help physicians assess the likelihood that a coronary artery blockage is limiting blood flow and support decisions about additional testing or treatment. Heartflow also offers related tools intended to assist with anatomical visualization, treatment planning and communication of cardiac imaging results.

Heartflow was founded in 2010 and is headquartered in Redwood City, California. Its technology is used by healthcare providers in the United States and international markets, including parts of Europe and Asia. The company commercializes its products through relationships with hospitals, health systems and other medical providers.

View Heartflow Profile
Earnings Tools